• Sarepta Therapeutics granted new CEO Michael Severino stock options for 2,224,342 shares and 756,104 restricted stock units on July 28, 2026.
• Options carry a $17.74 exercise price, set at a 15% premium to the stock’s July 28 closing price.
• Options vest 25% after one year, then monthly, reaching full vesting after four years.
• RSUs vest in four equal annual installments, reaching full vesting after four years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607291700BIZWIRE_USPR_____20260729_BW720331) on July 29, 2026, and is solely responsible for the information contained therein.